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1. Introduction
Ménière’s disease (MD) is probably a multifactorial disorder where the genetics 
and environmental factors determine the onset of the disease. This disease have 
been related to the accumulation of endolymph in the cochlear duct and the ves-
tibular organs in histopathological studies, although endolymphatic hydrops (EH) 
per se does not explain all clinical features, including the progression of hearing loss 
or the frequency of attacks of vertigo [1–4].
Dizziness and vertigo are frequent symptoms in the otolaryngologist’s practice, 
and all efforts towards the better comprehension of this system and its pathology 
are of fundamental importance [1, 2].
Currently, there is no universally accepted theory about the pathophysiology of 
the disease. Through histopathological studies, it is assumed that endolymphatic 
hydrops is the most descriptive pathological feature of Ménière’s disease. The patho-
physiology of symptoms is still widely disputed: membrane ruptures, increased 
pressure, and mechanical displacement of peripheral organs such as endolymph 
accumulation, viral infections, autoimmune disease, and several other theories that 
have been reported [1–3].
Great advances have been made in neuro-otology, and increasing knowledge 
in the field of molecular biology, genetics, and neurosciences has substantially 
modified the approach of the patient with balance complaints. This book studies 
the most interesting and controversial of these vestibular diseases, the Ménière’s 
disease.
The Classification Committee for the International Classification of Vestibular 
Disorders (ICVD) nominated by the Bárány Society, 2009, standardized the 
nomenclature of vestibular symptoms (SV) in four groups. One of the most impor-
tant is the episodic vestibular syndrome: crises of vestibular symptoms interspersed 
with asymptomatic periods, such as Ménière’s syndrome and vestibular migraine 
[1, 2–6].
Ménière’s disease is an inner ear alteration characterized by two groups of 
symptoms: vestibular and auditory symptoms. In many patients, their presentation 
may be unusual or different than the classical symptoms such as tinnitus, fluctuat-
ing hearing loss, aural fullness, and concomitant dizziness [1, 2].
The history of the disease may be progressive or nonprogressive, and, in addi-
tion to the typical clinical presentation of Ménière’s disease, two variants of the 
disease were identified:
1. cochlear Ménière’s disease—hearing is the predominant symptom; and
2. vestibular Ménière’s disease—vestibular symptoms are predominant.
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Other classifications used frequently are as follows:
1. Ménière’s syndrome: known and well-established condition causing symp-
toms; and
2. Ménière’s disease: idiopathic cause [1, 2].
Recent studies revealed that there are genotypic and phenotypic factors that 
influence the prevalence difference between countries [7].
In the majority of these patients, the initial presentation of the disease is often 
the cochlear form, which is harder to be clinically recognized and frequently is 
associated with another cause or is presumed to be simply due to aging.
Even after the vestibular component becomes obvious, long periods of remis-
sion may mask the complete final image of the syndrome with episodic vertigo, 
fluctuating autistic loss, tinnitus, and aural fullness. Therefore, generally in clinical 
practice, only moderate to severe cases are tabulated in the estimates so far.
A multifactorial inheritance is believed to be the best response, where the neces-
sary conditions are met, leading to endolymph malabsorption and subsequently 
hydrops. Clinical and laboratory evidence supports this concept. Merchant et al. 
analyzed the temporal bone collection of the Massachusetts Eye and Ear Infirmary, 
Harvard Medical School, Boston, USA, with a clinical diagnosis of Ménière’s 
syndrome (28 cases) or a histopathological diagnosis of hydrops (79 cases).
All 28 cases with classic symptoms of Ménière’s syndrome had hydrops in at least 
one ear. However, the reverse is not true. There were 9 cases of idiopathic hydrops 
and 10 cases with secondary hydrops, in which the patients did not have the clas-
sic symptoms of Ménière’s syndrome. Endolymph is mainly produced in the stria 
vascularis. Slowly, endolymph is absorbed into the endolymphatic duct and sac, a 
biologically active transport structure where absorption occurs mainly and also to 
a lesser extent secretion occurs. Evidence strongly suggests that longitudinal flow 
(slow process) and radial flow (fast) occur.
In this book we will adopt the term Ménière’s disease to follow the prevailing 
trend among most research groups and discuss the main topics, current and past 
ideas about etiopathogenesis, diagnosis, and treatment of Ménière’s disease associ-
ated with migraine.
Some of the epidemiologically published studies to date have tended to blend 
different epidemiological concepts. The direction of these studies is mainly 
 retrospective (the themes are identified after a result or illness), and they actually 
measure only the prevalence (existing events or the number of cases of a disease at a 
given moment divided by the population at risk). Only prospective studies (subjects 
are identified before a result or illness, future events are counted) would have the 
power to adequately measure this incidence. Although more reflective to real life than 
an artificial experiment, retrospective observational studies are susceptible to bias.
2. Diagnostic failures
There are many classifications and proposed diagnostic criteria, and it 
makes difficult to establish the true incidence of Ménière’s disease in the general 
population.
The 1995 and 2015 criteria simplified the definition of Ménière’s disease and 
allowed to be usable in all global studies and so may be able to substitute and unify 
all the classifications [1, 2].
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3. Etiopathogeny
Almost all the researchers and histopathological works in the past presumed that 
endolymphatic hydrops was the pathological characteristic of Ménière’s disease. 
There are still many questions and polemic discussions about the pathophysiology 
of the symptoms: increased pressure and mechanical displacement of the peripheral 
organs such as saccule by endolymph accumulation, ruptures of membranes, viral 
infections, and autoimmune disease, in addition to several other theories that have 
already been reported.
Recent consensus accepted that endolymphatic hydrops is no longer a central 
etiology but rather as one of the manifestations of the syndrome.
4. Diagnostic
Classical Ménière’s disease is an excellent example of a condition that can be 
diagnosed on clinical grounds and simple audiometric examinations.
When it is the classic or definite form, it is characterized by recurrent and 
spontaneous episodes of vertigo, fluctuating sensorineural hearing loss,  tinnitus, 
and aural fullness. In this case the diagnosis is easy even for the most naive 
 clinician [1, 2].
In 2015, the Hearing and Balance Committee of the American Academy of 
Otorhinolaryngology-Head and Neck Surgery (AAO-HNS), Bárány Society, and 
other entities set the parameters for the clinical diagnosis of Ménière’s disease.
The classification includes two categories: defined Ménière’s disease and prob-
able Ménière’s disease [2].
Defined Ménière’s disease is based on clinical criteria and requires the observa-
tion of an episodic vertigo syndrome associated with low- to medium-frequency 
sensorineural hearing loss and fluctuating auditory symptoms (tinnitus in the ear 
and/or fullness) in the affected ear.
The duration of vertigo episodes is limited to a period of between 20 minutes 
and 12 hours. Probable Ménière’s disease is a broader concept defined by episodic 
vestibular symptoms (vertigo or dizziness) associated with fluctuating aural symp-
toms that occur over a period of 20 minutes to 24 hours [1, 2].
The clinical evaluation then includes the following [8, 9]:
• detailed medical history that should include all previous vertigo events;
• laboratory tests to rule out differential diagnoses of the syndrome;
• imaging tests to aid diagnosis and rule out differential diagnoses of the syn-
drome; and
• cochlear and vestibular, audiological, and electrophysiological examinations.
The most appropriate exams to aid in diagnosis consist of:
• glycerol dehydration test;
• electrocochleography (ECochG); and
• PEMV or VEMP test.
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5. Treatment
Different treatment options for Ménière’s disease exist with substantial vari-
ability between countries. None of the treatment options cure the disease. As many 
treatments have a significant impact on the functioning of surrounding structures, 
one should start with noninvasive approaches with the fewest possible side effects 
and proceed to more invasive steps:
• conservative;
• diet;
• diuretics;
• labyrinth suppressors;
• invasive procedures;
• intratympanic gentamicin;
• endolymphatic sac decompression surgery;
• labyrinthectomy; and
• vestibular neurectomy.
Sodium restriction diet: Low-level evidence suggests that restricting the sodium 
intake may help to prevent Ménière’s attacks.
Betahistine: Substantial disagreement in the medical community about the use 
of betahistine exists. A Cochrane review found low-level evidence to support the 
use of betahistine with substantial variability between studies. Medical therapy in 
many medical centers often starts with betahistine orally.
Intratympanic steroid injections may reduce the number of vertigo attacks in 
patients with Ménière’s disease.
Intratympanic gentamycin injections: Gentamycin has strong ablative properties 
towards vestibular cells. The side effects are a sensorineural hearing loss because of 
a certain amount of toxicity towards cochlear cells.
Surgery with vestibular nerve section or labyrinthectomy: Nerve section is a 
therapeutic option in patients who failed the conservative treatment options and 
labyrinthectomy when surgical options failed. Labyrinthectomy leads to a complete 
hearing loss in the affected side.
Clinically, three situations arise in which drug treatment is very helpful:
6. Acute attack drugs
Aiming at sedating the vestibule-trunk axis is particularly useful in aborting 
acute attacks. These include cinnarizine, promethazine, and diazepam.
Prolonged use of drugs such as cinnarizine is not advisable due to the risk of 
extrapyramidal side effects from prolonged use, particularly in the elderly.
6.1 Maintenance treatment
Dietary salt restriction and the use of diuretics such as furosemide, amiloride, 
and hydrochlorothiazide are attempts to prevent endolymphatic hydrops. The basis 
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for this is historical rather than scientific, as the data from the few controlled stud-
ies that exist are conflicting and the placebo effect is clinically significant.
Betahistine has been subject to some scientific scrutiny, and several controlled 
clinical studies have shown significant improvement in vertigo, hearing loss, and 
tinnitus in the short term. Betahistine, with or without a diuretic, is currently the 
preferred means of ensuring medical treatment.
Drugs such as cinnarizine, propranolol (particularly if the patient has a history 
of migraine), and corticosteroids are also used empirically by some doctors if the 
patient’s symptoms are refractory to the above measures.
7. Ablative treatment
7.1 Intratympanic gentamicin
The toxic effects of aminoglycosides on the inner ear sensory neuroepithelium 
have been recognized for decades.
Chemical labyrinthectomy through intratympanic gentamicin (GIT) controls 
vertigo and has been helpful in mainly unilateral Ménière’s disease when hearing is 
poor, but the vertigo presented by the patient is disabling.
The attending otologist should properly remind and advise the patient that 
from 3 days after the first application, fiber differentiation begins to occur and this 
usually leads to severe vestibular symptoms between 7 and 10 days after application. 
And it is a phenomenon expected by the chemical destruction of vestibular nerve 
afferents.
Several series have a vertigo control rate of about 90%, although a cochleotoxic 
effect is seen in 15–25% of cases. The future for intratympanic aminoglycosides in 
Ménière’s disease is therefore very promising [10].
Protocol of use:
• Complete battery of vestibular tests before therapy
• Initial reference (VENG before GIT)
• Provide for college entrance compensation
• Intratympanic gentamicin (40 mg/ml)
• Weekly intervals (up to three to four applications)
• Repeat audiometry weekly
• Repeat the VENG at the end of the sessions
• Topical anesthesia
• Patient rests for 1 hour after application
7.2 Surgical treatment
Whether as a result of medical treatment or as a consequence of the  clinical 
course of Ménière’s disease, about 90% of patients have a long period of 
remission.
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This implies that 10% of patients continue to have clinically important episodes 
of vertigo, and surgical treatment should be considered for them.
The various surgical procedures advocated for Ménière’s disease continue to raise 
considerable controversy among otolaryngologists. The decision to operate and the 
choice of procedure are often dictated by the understanding and experience of a 
particular technique and the surgeon’s individual threshold for surgical interven-
tion. Generally, surgical procedures for Ménière’s disease are classified as destruc-
tive or nondestructive with regard to hearing [8–10].
7.3 Endolymphatic sac surgery
Endolymphatic sac surgery was first described in 1927 by Portmann, and no 
other aspect of Ménière’s disease has elicited further debate or controversy. Just 
as the exact role of the endolymphatic sac in the development of hydrops is not 
yet known, the precise mechanism by which surgery works remains undefined. 
However, endolymphatic sac decompression surgery is still widely performed [10].
7.4 Vestibular nerve section
In the vestibular nerve section, no attempt is made to modify the underlying 
pathophysiology. The objective is to dissociate the offensive maze from the trunk, 
preserving the patient’s hearing.
The procedure is uniformly effective, with vertigo control in 90–95% of patients 
according to some series. However, it is a surgery with considerable risks inherent in 
any posterior fossa neurosurgical procedure [10].
7.5 Surgical labyrinthectomy
Labyrinth extirpation is indicated in patients with severe symptoms who have 
virtually useless hearing. Disturbance of the inner ear thus invariably leads to 
permanent anacusis. However, the ear on the opposite side may have subclinical 
hydrops, and we should be naturally concerned that the progress of the disease in the 
patient’s contralateral ear may aggravate and make it bilaterally deaf. This is probably 
the reason for the widespread choice of nondestructive inner ear procedures [10].
7.6 Cochlear implant
Over the past decade, the hearing rehabilitation of certain profoundly deaf 
people has been transformed by cochlear implants.
Patients with severe bilateral Ménière’s disease and severe to profound bilateral 
sensorineural deafness will end up with an indication for hearing rehabilitation 
with cochlear implant. Surgeons with patients with symptoms whose disease is 
refractory to clinical treatment have several surgical options.
We should always start with the use of intratympanic aminoglycosides as the 
least aggressive option.
When intratympanic gentamicin does not work, there are three management 
strategies: proponents of endolymphatic sac surgery as the first surgical step, 
reserving revision surgery, or vestibular neurectomy for patients who continue to 
have vertigo.
Patients who have not yet achieved clinical improvement after the endolym-
phatic sac decompression operation, the otologist who has no experience or staff to 
subject the patient to vestibular neurectomy is faced with the option of performing 
surgical labyrinthectomy [10].
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